Resveratrol COVID-19 outcomes
November 2026
StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
McCreary (DB RCT)67%0.33 · 0.04–3.10hosp.1/503/50
McCreary (DB RCT)43%0.57 · 0.18–1.83progression4/507/50
McCreary (DB RCT)50%0.50 · 0.16–1.55progression4/508/50
McCreary (DB RCT)0%1.00 · 0.06–15.55progression1/501/50
Mittra44%0.56 · 0.26–1.02death7/3089/200RESCU 002CT1
Kaplan (RCT)−14%1.14 · 0.08–16.63ventilation1/141/16ReszinateCT1
Kaplan (RCT)−14%1.14 · 0.08–16.63ICU1/141/16ReszinateCT1
Kaplan (RCT)−14%1.14 · 0.08–16.63hosp.1/141/16ReszinateCT1
00.511.52+